CD44 and neoplasm: In a univariate analysis, the patients with “high” CD44+/CD24− tumours displayed a shorter median MFS (18 months) than those with “low” CD44+/CD24− tumours (median MFS not reached; p = 0.004; Figure 3 and Table 3).